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SUMMARY
Background
Small-intestinal bacterial overgrowth (SIBO) is known to be present in
patients with cirrhosis, predisposing to various complications.
Aim
To determine the frequency of SIBO in cirrhotics and correlate with
severity of cirrhosis.
Methods
Small-intestinal bacterial overgrowth was determined by glucose–
hydrogen breath test (GHBT). A basal breath-hydrogen >20 ppm or a
rise by ‡12 ppm above baseline following glucose administration was
taken as positive test. Prevalence of SIBO in cirrhotics was compared
with healthy controls and correlated with severity of cirrhosis.
Results
Of the 53 cirrhotics, 26 (49%) had SIBO, compared to one (8%) control
(P = 0.010). The prevalence of SIBO increased with severity of cirrhosis
(Child–Pugh A 20%, B 52% and C 73%; P = 0.013). On multivariate
analysis, SIBO was independently associated with serum bilirubin and
ascites. The best cut-off of serum bilirubin was ‡2 mg ⁄dL [AUROC 0.77
(95% CI 0.64–0.90)] predicting SIBO with sensitivity 65%, specificity
81%, positive predictive value 77%, negative predictive value 71% and
accuracy 74%. Patients having combination of ascites and serum biliru-
bin ‡2 mg ⁄dL had 82% chance, while patients having neither had only
10% chance of having SIBO.
Conclusions
Small-intestinal bacterial overgrowth was prevalent in about half of cir-
rhotics. Its frequency increased with increase in severity of cirrhosis.
Ascites and raised serum bilirubin reliably predicted presence of SIBO.
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INTRODUCTION
Derangement of gut flora, in particular, small-intesti-
nal bacterial overgrowth (SIBO) is highly prevalent in
patients with cirrhosis.1–3 Significantly increased
counts of both Gram-positive and -negative bacterial
species have been recovered from faeces of cirrhotic
patients.4 This has been attributed, at least in part, to a
decrease in small intestinal motility and increased
adrenergic activity due to cirrhosis.2, 3, 5–7
In addition to the range of symptoms and conse-
quences of SIBO per se, increasing evidence suggests
that derangement of gut flora is of substantial clinical
relevance to patients with cirrhosis. SIBO and
increased bacterial translocation of gut flora from the
intestinal lumen, in combination with failure of
immune defence mechanisms to remove efficiently
these translocating microorganisms, predispose to an
increased potential for bacterial infections like sponta-
neous bacterial peritonitis (SBP) and sepsis in this
group.3, 8 Recent studies also suggest that gut flora,
both in the colon and small intestine, may contribute
to the proinflammatory state of cirrhosis even in the
absence of overt infection.9 Furthermore, manipulation
of gut flora, to augment the intestinal content of lactic
acid-type bacteria at the expense of other gut flora
species with more pathogenic potential, may favour-
ably influence liver function in cirrhotic patients.10
There are scanty data in literature about the preva-
lence of SIBO in cirrhotics and its relationship to
severity of liver disease. A relationship has been
reported between the severity of liver failure and the
intensity of small intestinal motility disturbances.11
Such disturbances could play a role in the pathogene-
sis of SIBO and even lead to complications of cirrho-
sis, such as SBP and encephalopathy. A high
prevalence of SIBO has been observed in patients with
liver cirrhosis with SBP.3
We hypothesized that severity of liver disease and
hepatic decompensation can have a pathogenic role in
altering the small intestinal bacterial contents in cir-
rhotic patients; we tested this hypothesis by comparing
presence of SIBO in subjects with and without cirrho-
sis and among patients with varying severity of cir-
rhosis. We used glucose–hydrogen breath test (GHBT),
the most commonly used non-invasive test, to diag-
nose SIBO. We also tried to associate various clinical
and laboratory parameters with presence of SIBO. We
believe that this information would help in prevention
of some of the serious complications of cirrhosis by
identifying patients with SIBO by simple clinical and
laboratory parameters and targeting therapy against
bacterial overgrowth in this high-risk population.
PATIENTS AND METHODS
Patients
Inclusion criteria. All consecutive patients of cirrho-
sis, attending the out-patient or in-patient departments
of our hospital were included in the study. Controls
were healthy subjects who were not on any probiotic
supplements.
Exclusion criteria. Patients with gastro-intestinal
bleed, hepatic encephalopathy and sepsis in previous
4 weeks; and significant pulmonary disease were
excluded from the study. Patients on probiotics or acid-
suppressive therapy were also excluded. Antibiotics, if
any, were stopped 7 days prior to the study and lactu-
lose was stopped 2 days before the study. Patients on
immunosuppressives or narcotics were also excluded.
Cirrhosis was diagnosed by clinical, biochemical, his-
tological or imaging studies. Each patient underwent
detailed clinical evaluation and investigations to
determine the aetiology and severity of liver disease.
The laboratory investigations included serum bilirubin,
serum creatinine, serum albumin and prothrombin time.
Portal hypertension was assessed by endoscopic
evidence of varices and hepatic venous pressure gradi-
ent (HVPG) measurement in a subgroup of patients.
Cirrhosis was said to be compensated if there was no
clinical ascites, clinical jaundice or history of variceal
bleed.
Glucose–hydrogen breath test
Glucose–hydrogen breath test was performed using a
breath gas analyzer (Micro H2; Micro Medical Limited,
Kent, UK). The subjects were asked to avoid slowly
absorbed carbohydrates (bread, potato, corn) and fibre
the previous evening to avoid delayed excretion of
hydrogen in the breath.12 Basal breath specimens were
obtained after the overnight fast. Cigarette smoking
and physical exercise were not permitted for 2 h
before and during the test, to prevent hyperventilation
and consequent changes in breath hydrogen content.13
The subjects then brushed their teeth, rinsed their
mouths with an antiseptic wash followed by tap water,
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to eliminate an early hydrogen peak due to action of
oral bacteria on test sugars.14 An average of four val-
ues was taken as the basal breath hydrogen level. Sub-
jects then ingested 100 g glucose dissolved in 200 mL
water. Thereafter, breath hydrogen was estimated
every 15 min for 3 h. An increase in hydrogen excre-
tion, in parts per million (ppm), following glucose
administration, was calculated by subtracting the fast-
ing value from the highest value of hydrogen excre-
tion obtained. A rise of breath hydrogen by ‡12 ppm
above basal level following glucose administration
was taken as evidence of SIBO.15 Average value of
basal breath hydrogen >20 ppm despite adequate prep-
aration for breath test on at least 2 days was consid-
ered as high basal breath hydrogen and this was also
considered as positive test.16 Nonhydrogen producer
status was confirmed by lactulose–hydrogen breath
test.17
HVPG measurement
Hepatic venous pressure gradient was measured after
the breath analysis test, in a subgroup of patients who
consented for the procedure. HVPG measurement was
performed after overnight fast, and under antibiotic
cover. Under local anaesthesia, a 7F central venous
catheter (Arrow Medical, Athens, TX, USA) was placed
in the right femoral vein or internal jugular vein under
fluoroscopic guidance, using the Seldinger technique.
HVPG was measured by the standard technique18 in
which a balloon catheter was introduced into the right
hepatic vein under fluoroscopic guidance. The zero
reference point was set at the mid-axillary point. The
free hepatic venous pressure (FHVP) was obtained by
keeping the catheter free into the lumen of the hepatic
vein. The balloon of the catheter was then inflated to
wedge the lumen of hepatic vein. Presence of wedging
was confirmed by absence of reflux into the inferior
vena cava, after the injection of 2 mL intravenous
contrast, and appearance of a sinusoidogram. The
pressure tracing at this juncture showed absence of
wave forms and the pressure was labelled as wedged
hepatic venous pressure (WHVP). HVPG was deter-
mined by subtracting free from WHVPs (HVPG =
WHVP ) FHVP). All measurements were performed in
triplicate. If the difference between the two readings
was more than 1 mmHg, all the readings were dis-
carded and fresh set of measurements were taken. The
normal value of the HVPG in our hemodynamic labo-
ratory is between 1 and 4 mmHg.
Calculations and statistical analyses
Prevalence of SIBO in cirrhotics was compared with
healthy controls. Additionally, prevalence of SIBO was
correlated with severity and aetiology of liver disease.
The results were expressed as mean with standard
deviation (s.d.) or median with range. Comparisons
between groups were performed by using Student’s
t test, Mann–Whitney U-test or Pearson’s chi-square
test with Yates’ continuity correction. A value of
P < 0.05 was taken as significant. All statistical analy-
ses were performed using the SPSS 15.0 statistical pack-
age (SPSS Inc., Chicago, IL, USA).
RESULTS
Patient characteristics
Eighty-nine patients of cirrhosis were enrolled in the
study; 27 were excluded due to following reasons:
gastro-intestinal bleed in previous 4 weeks (n = 14),
hepatic encephalopathy (n = 5), bacterial infections
with sepsis (n = 4), hepato-pulmonary syndrome
(n = 2), chronic obstructive pulmonary disease
(n = 1) and significant pleural effusion (n = 1).
Remaining, 62 patients were included in the study.
Six patients were on antibiotics for secondary prophy-
laxis of SBP, which was stopped 7 days prior to the
study.
The baseline characteristics of included patients are
given in Table 1. The mean age of patients was 42
(15) years, and 50 (81%) were males. The most com-
mon aetiologies of cirrhosis were hepatitis B (34%),
alcohol (26%) and cryptogenic (21%). None of the
patients with alcoholic liver disease was actively con-
suming alcohol. For comparison, 15 age- and gender-
matched healthy controls were included.
Results of breath analysis
Nine of 62 patients (14%) and 2 of 15 (13%) healthy
controls were nonhydrogen producers (P = 0.906)
(Table 2). SIBO could be assessed in remaining 53
patients and 13 controls.
Twenty-six of 53 (49%) patients were positive for
SIBO compared to only one of 13 (8%) controls
(P = 0.010). Positivity by high baseline breath hydro-
gen (‡20 ppm) criteria was in 16 (62%) positive
patients and none (0%) of the controls while positivity
by rise (‡12 ppm) over baseline criteria was in 10
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(38%) positive patients and one (100%) controls
(P = 0.219) (Table 2).
Association of SIBO with severity of liver
disease, portal hypertension and aetiology
Small-intestinal bacterial overgrowth was more preva-
lent in patients with decompensated cirrhosis than in
patients with compensated cirrhosis. Among patients
with compensated cirrhosis, SIBO was present in three
of 15 (20%), while in patients with decompensated cir-
rhosis, SIBO was present in 23 ⁄38 (61%) (P = 0.019).
Prevalence of SIBO increased progressively with
increase in Child–Turcotte–Pugh (CTP) class. The prev-
alence of SIBO in patients with CTP class A was 20%
(3 ⁄15), with CTP class B was 52% (12 ⁄23) and with
CTP class C was 73% (11 ⁄15) (P = 0.013) (Figure 1).
The mean CTP score in patients with SIBO was
9.2  1.9, while it was 7.4  2.1 in patients without
SIBO (P = 0.001) (Figure 2).
Patients with serum bilirubin ‡1.4 mg ⁄dL had higher
frequency of SIBO [19 ⁄30 (63%)] than patients with
Table 1. Baseline characteristics of included patients
Parameter
Cases
(n = 62)
Healthy
controls
(n = 15) P-value
Mean (s.d.) age,
years
42 (14) 36 (12) 0.131
Male:female, n 50:12 11:4 0.531
Aetiology of cirrhosis, n (%)
Hepatitis B 21 (34)
Alcohol 16 (26)
Cryptogenic 13 (21)
Hepatitis C 10 (16)
Other 2 (3)
History of variceal
bleed, n (%)
25 (40)
History of SBP, n (%) 6 (10)
History of chronic
diarrhoea, n (%)
2 (3)
Ascites, n (%)
Absent 38 (61)
Present 24 (39)
Median (range) serum
bilirubin, mg ⁄ dL
1.4 (0.3–9.4)
Prothrombin time prolongation in s, n (%)
0–3 22 (35.5)
4–6 18 (29)
>6 22 (35.5)
Mean (s.d.) serum
albumin, g ⁄ dL
3.2 (0.7)
Mean (s.d.) serum
creatinine, mg ⁄ dL
0.9 (0.5)
Varices, n (%)
Small (<5 mm) 32 (52)
Large (‡5 mm) 30 (48)
Mean (s.d.) HVPG*,
mmHg
16.5 (5.1)
CTP class, n (%)
A 18 (29)
B 28 (45)
C 16 (26)
Median (range) CTP
score, n ⁄ 15
8 (5–13)
Status of cirrhosis, n (%)
Compensated 18 (29)
Decompensated 44 (71)
* HVPG was measured in 30 patients.
s.d., standard deviation, SBP, spontaneous bacterial peritoni-
tis; HVPG, hepatic venous pressure gradient; CTP, Child–
Turcotte–Pugh.
Table 2. Results of glucose hydrogen breath analysis
Status
Cases
(n = 62),
n (%)
Healthy
controls
(n = 15),
n (%) P-value
Nonhydrogen producers 9 (14) 2 (13) 0.906
Negative breath hydrogen test 27 (44) 12 (80) 0.010
Positive breath hydrogen test 26 (42) 1 (7) 0.010
High baseline criteria 16 (62) 0 (0)
Rise criteria 10 (38) 1 (100)
Figure 1. Frequency of small-intestinal bacterial over-
growth (SIBO) in Child–Turcotte–Pugh (CTP) class A, B
and C.
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serum bilirubin <1.4 mg ⁄dL [7 ⁄23 (30%); P = 0.036].
Similarly, patients with low serum albumin (<3.2 g ⁄dL)
had higher frequency of SIBO than patients with high
albumin (P = 0.020). However, no association could be
found between derangement of prothrombin time and
presence of SIBO (P = 0.338). SIBO was present more
frequently in patients with ascites than in patients with-
out ascites [16 ⁄22 (72%) vs. 10 ⁄31 (32%); P = 0.009].
We had very few patients who had history of SBP
(n = 6), hence no association could be found with these
patients and presence of SIBO.
Among patients with large oesophageal varices
(‡5 mm) 15 ⁄28 (54%) had SIBO while among patients
with small oesophageal varices, 11 ⁄25 (44%) had SIBO
(P = 0.674). Among patients who had history of vari-
ceal bleed in past, 12 ⁄20 (60%) had SIBO, while
among patients who were nonbleeders, 14 ⁄33 (42%)
had SIBO (P = 0.338). In a subgroup analysis of
patients whose HVPG values were available (n = 30),
no significant association could be found with HVPG
and SIBO (P = 0.165).
Patients with cirrhosis due to hepatitis C had lower
prevalence of SIBO [1 ⁄8 (13%)] compared with cirrho-
sis due to other aetiology [25 ⁄45 (56%)]; however, it
did not reach statistical significance (P = 0.063). There
was no correlation of presence of SIBO with other
aetiologies of liver disease (Table 3).
Hence, on univariate analysis, SIBO was signifi-
cantly associated with ascites, high serum bilirubin,
Figure 2. Mean (s.d.) and individual values of Child–
Turcotte–Pugh (CTP) score in patients with and without
small-intestinal bacterial overgrowth (SIBO).
Table 3. Association of various parameters with presence
of small intestinal bacterial overgrowth
Parameter
Patients
with SIBO
(n = 26),
n (%)
Patients
without
SIBO
(n = 27),
n (%) P-value
Age, years
<42 12 (46) 9 (33) 0.501
‡42 14 (54) 18 (67)
Gender
Males 19 (73) 24 (89) 0.263
Females 7 (27) 3 (11)
Aetiology of cirrhosis
HBV
HBV 10 (38) 8 (30) 0.698
NonHBV 16 (62) 19 (70)
Alcohol
Alcohol 7 (27) 6 (22) 0.938
Non-alcohol 19 (73) 21 (78)
Cryptogenic
Cryptogenic 7 (27) 5 (18) 0.687
Noncryptogenic 19 (73) 22 (82)
HCV
HCV 1 (4) 7 (26) 0.063
NonHCV 25 (96) 20 (74)
History of variceal bleed
Yes 12 (46) 8 (30) 0.338
No 14 (54) 19 (70)
History of SBP
Yes 3 (12) 3 (11) 1.000
No 23 (88) 24 (89)
History of chronic diarrhoea
Yes 2 (8) 0 (0) 0.454
No 24 (92) 27 (100)
Ascites
No 10 (38) 21 (78) 0.009
Yes 16 (62) 6 (22)
Serum bilirubin, mg ⁄ dL
<1.4 7 (27) 16 (59) 0.036
‡1.4 19 (73) 11 (41)
Prothrombin time prolongation, s
0–6 14 (54) 19 (70) 0.338
>6 12 (46) 8 (30)
Serum albumin, g ⁄ dL
<3.2 17 (65) 8 (30) 0.020
‡3.2 9 (35) 19 (70)
Serum creatinine, mg ⁄ dL
<0.9 15 (58) 13 (48) 0.674
‡0.9 11 (42) 14 (52)
Varices
Small (<5 mm) 11 (42) 14 (52) 0.674
Large (‡5 mm) 15 (58) 13 (48)
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low serum albumin, high CTP score and decompensat-
ed cirrhosis (Table 3). When ascites, bilirubin and
albumin were entered into multivariate analysis pres-
ence of SIBO was independently associated with pres-
ence of ascites (P = 0.011) and serum bilirubin level
(P = 0.050) (Table 4).
Using serum bilirubin as test variable to predict pres-
ence of SIBO, an ROC curve was prepared (Figure 3).
The area under ROC curve (AUROC) was 0.77 (95% CI
0.64–0.90). Based on the ROC curve the best cut-off of
serum bilirubin obtained was ‡2 mg ⁄dL which pre-
dicted SIBO with sensitivity of 65%, specificity of 81%,
positive predictive value of 77%, negative predictive
value of 71%, and accuracy of 74%. Patients having
combination of ascites and serum bilirubin ‡2 mg ⁄dL
had 82% chance of having SIBO, while patients having
neither of these had only 10% chance of having SIBO.
Patients having one of these parameters had intermedi-
ate probability of SIBO (Figure 4).
DISCUSSION
The results of this novel study, using GHBT in cirrho-
tics, clearly show that SIBO is more prevalent in
patients with cirrhosis than healthy subjects. More-
over, the prevalence of SIBO increases with severity of
liver disease as determined by the CTP score. Presence
of ascites and high serum bilirubin were independently
associated with presence of SIBO.
SIBO can be diagnosed by several methods. We used
GHBT to diagnose SIBO. We used the criteria of rise of
breath hydrogen by ‡12 ppm above basal level follow-
ing glucose administration or a high baseline breath
Table 3. (Continued)
Parameter
Patients
with SIBO
(n = 26),
n (%)
Patients
without
SIBO
(n = 27),
n (%) P-value
HVPG (n = 30), mmHg
<16.5 5 (38) 12 (71) 0.165
‡16.5 8 5 (29)
CTP class
A ⁄B 15 (12) 23 (44) 0.055
C 11 (46) 4 (41)
CTP score
<8 4 (15) 14 (52) 0.012
‡8 22 (85) 13 (48)
Status of cirrhosis
Compensated 3 (12) 12 (44) 0.019
Decompensated 23 (88) 15 (56)
Grouping of various parameters is based on their mean or
median values.
HBV, hepatitis B virus; HCV, hepatitis C virus; SBP, sponta-
neous bacterial peritonitis; HVPG, hepatic venous pressure
gradient; CTP, Child–Turcotte–Pugh.
Figure 3. Receiver operating characteristic curve for
serum bilirubin in predicting small-intestinal bacterial
overgrowth. AUROC, area under receiver operating char-
acteristic curve.
Figure 4. Frequency of small-intestinal bacterial over-
growth (SIBO) in patients with and without ascites and
serum bilirubin (Bil) <2 or ‡2 mg ⁄ dL.
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hydrogen value of ‡20 ppm to diagnose SIBO. These are
the most validated criteria of GHBT to diagnose
SIBO.15, 16, 19 Bauer et al.20 had suggested that, in
patients with cirrhosis, the GHBT correlates poorly with
the diagnostic gold standard for SIBO. The gold stan-
dard is aspiration and culture of small bowel contents.
This method is invasive, requiring intubation of the
small bowel and a laboratory equipped with isolating
anaerobes and is uncommon in general practice. Hence,
GHBT remains the most commonly used non-invasive
test to diagnose SIBO. The sensitivity and specificity of
breath tests are variable; sensitivities as low as 62% and
as high as 93% have been reported for GHBT.15, 21
We included 62 patients of cirrhosis of mixed aetiol-
ogy in our study. We sought association of various
severity parameters of liver disease with presence of
SIBO. Patients included in our study were a carefully
selected homogenous group of cirrhotics, without
recent gastro-intestinal bleed, hepatic encephalopathy,
sepsis, pulmonary disease, and not on treatment with
probiotics, acid-suppressants, antibiotics, lactulose, im-
munosuppressives and narcotics. Unlike previous stud-
ies, our study excluded various extraneous influences,
which could have affected the frequency of SIBO in
cirrhotics.
Approximately 14% patients and 13% controls were
nonhydrogen producers in our study. This frequency
of nonhydrogen producers is consistent with other
studies.22, 23
We found that nearly half of patients with cirrho-
sis have SIBO compared to <10% healthy controls.
Thus, SIBO forms an important component of varied
manifestations of cirrhosis. The association between
cirrhosis and SIBO was first reported in 1957.24 Since
then, several studies have confirmed the high preva-
lence of SIBO among patients with cirrhosis.2, 25–27
Chesta et al.25 demonstrated SIBO by jejunal cultures
in 64% and by lactulose–H2 breath test in 45% of
cirrhotics. Bauer et al.2 found SIBO by jejunal cul-
tures to be present in 61% of cirrhotics. Gunnarsdot-
tir et al.26 found SIBO in 33% of cirrhosis with
portal hypertension, but none in the cirrhosis without
portal hypertension. In a study by Morencos et al.27
on 89 patients with alcoholic cirrhosis and 40
healthy subjects, SIBO was documented in 30% of
patients with alcoholic cirrhosis and in none of the
healthy subjects.
In our study, SIBO was more prevalent in patients
with Child’s C than Child’s A cirrhosis. SIBO was pres-
ent in 61% of decompensated cirrhotics, three times
more common than in compensated cirrhotics. More-
over, prevalence of SIBO increased progressively with
increase in CTP class. Morencos et al.27 and Yang
et al.28 found that CTP class had a significant influ-
ence on prevalence of SIBO. Madrid et al.11 studied
small bowel motility in cirrhosis patient. He noted that
absence of cyclic activity was most frequently
observed in Child–Pugh stage C patients compared to
Child–Pugh stage A cirrhotics. A significant increase
in clustered contractions in class C was recorded. The
frequency and amplitude of contractions were also
increased in CTP class C.
Among the components of CTP score, serum biliru-
bin, serum albumin and ascites correlated with SIBO
while prothrombin time prolongation did not correlate.
We could not correlate the presence of development of
hepatic encephalopathy with SIBO as we had excluded
these patients as per the study design. In Morencos
et al.’s study27 of alcoholic cirrhosis, the prevalence of
SIBO was higher in cirrhotics with ascites than in
those without ascites (37.1% vs. 5.3%); however, Yang
et al.28 did not find any relationship with the presence
or absence of ascites.
We had very few patients who had history of SBP
(n = 6); hence, no correlation could be found with
these patients and presence of SIBO. In the study by
Morencos et al.,27 the prevalence of SBP was higher in
patients who had SIBO (31%) than in patients who did
not (9%). The authors concluded that SIBO may be a
condition favouring infection of the ascitic fluid. How-
ever, Bauer et al.2 did not find SIBO to be associated
with SBP.
All patients in our study had portal hypertension
as documented by presence of varices. However, the
degree of portal hypertension as assessed by the size
of oesophageal varices or HVPG did not correlate
with SIBO. The frequency of SIBO was not different
between patients who had large or small varices.
Table 4. Results of multivariate analysis of parameters
associated with small-intestinal bacterial overgrowth
Parameter P-value Odds ratio 95% CI
Ascites present 0.011 5.02 1.44, 17.54
Serum bilirubin
‡1.4 mg ⁄ dL
0.050 3.45 1.00, 11.90
Ascites, serum bilirubin and serum albumin were entered
into multivariate analysis.
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Similarly, there was no difference in the frequency of
SIBO between patients with or without a past history
of variceal bleed. We did not include any patient
with recent (<4 weeks) history of gastro-intestinal
bleed. In a subgroup analysis of patients whose
HVPG values were available (n = 30), presence of
SIBO was not associated with higher HVPG. No pre-
vious study has correlated degree of portal hyperten-
sion with SIBO.
In various studies, alcohol (with or without liver dis-
ease) seems to be an important cause of SIBO.29, 30 Sa-
dik et al.7 found that small-bowel residence time was
longer in male patients with alcoholic cirrhosis com-
pared with male patients with other causes of portal
hypertension, suggesting that aetiology of liver disease
and gender may influence transit in patients with por-
tal hypertension. In a study by Bode et al.30 in patients
with alcohol abuse, SIBO was almost three times (38%)
that of controls not abusing alcohol (13.3%;
P < 0.001). However, evaluation of alcoholics with cir-
rhosis in comparison with those without cirrhosis
revealed no significant difference in the incidence of
SIBO. Similarly in studies by Chesta et al.25 and Yang
et al.,28 there was no difference in SIBO among vari-
ous causes of cirrhosis. In our study too, there was no
correlation of presence of SIBO with the aetiologies of
liver disease (Table 3).
On multivariate analysis, presence of SIBO was inde-
pendently associated with serum bilirubin level and
presence of ascites. The best cut-off of serum bilirubin
obtained was ‡2 mg ⁄dL, which predicted SIBO with an
accuracy of 74%. Moreover, patients having combina-
tion of ascites and serum bilirubin ‡2 mg ⁄dL had 82%
chance of having SIBO, while patients having neither
of these had only 10% chance of having SIBO. These
two simple clinical and laboratory parameters are
excellent in predicting SIBO and can be used in clini-
cal setting in situations where breath analysis or jeju-
nal aspiration is not possible.
There are some limitations to our study. First, we
did not use jejunal aspiration and culture to diagnose
SIBO, which is considered the gold standard. This
method is invasive requiring intubation of the small
bowel and a laboratory equipped with isolating
anaerobes. GHBT has remained the most commonly
used non-invasive test to diagnose SIBO in most pre-
vious studies. Second, the present study is cross-sec-
tional and patients with and without SIBO were not
prospectively followed-up to document differences in
outcome. Third, we did not have control group of
patients with chronic hepatitis without cirrhosis,
which could have sought an association between
SIBO and a wider spectrum of severity of liver dis-
ease. Fourth, caution should be exercised in the inter-
pretation of HVPG data. HVPG values are available
only in 30 subjects and the study may not be pow-
ered to detect a difference in HVPG between SIBO
positive and negative.
In conclusion, our study showed that SIBO was pre-
valent in about half of cirrhotics and its frequency
increased with the increase in severity of liver disease.
Presence of ascites and serum bilirubin ‡2 mg ⁄dL are
excellent parameters in predicting SIBO. Further pro-
spective studies are needed to document difference in
outcome between patients with and without SIBO and
the influence of treating SIBO on survival.
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STUDY HIGHLIGHTS
What is current knowledge?
• Small-intestinal bacterial overgrowth (SIBO) is
present in cirrhotics.
• It is thought to predispose to spontaneous bacte-
rial peritonitis and hepatic encephalopathy.
• It also causes a proinflammatory state in these
patients.
• Its correlation with severity of liver disease and
portal hypertension is uncertain.
What is new here?
• Nearly half of patients of cirrhosis have SIBO.
• The frequency of SIBO increases with severity of
liver disease.
• Small-intestinal bacterial overgrowth does not
correlate with severity of portal hypertension.
• Combination of ascites and high serum biliru-
bin can reliably predict presence of SIBO in these
patients.
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